Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10267038 | 0.81 | CYP1A2 (0.34) | KMT2ABRD4CYP1A2HIF1AALDH1A1 | |
| SCHEMBL2904103 | 0.81 | KMT2A (0.36) | KMT2ABRD4CYP1A2HIF1AALDH1A1 | |
| SCHEMBL172419 | 0.79 | ALDH1A1 (0.45) | KMT2AALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL7783338 | 0.78 | KMT2A (0.34) | KMT2ABRD4 | |
| SCHEMBL4703163 | 0.77 | ALDH1A1 (0.43) | KMT2AALDH1A1HSD17B10 | |
| SCHEMBL10362738 | 0.77 | ALDH1A1 (0.43) | KMT2AALDH1A1HSD17B10 | |
| SCHEMBL4703164 | 0.77 | ALDH1A1 (0.43) | KMT2AALDH1A1HSD17B10 | |
| SCHEMBL28798717 | 0.76 | KMT2A (0.32) | KMT2A | |
| SCHEMBL9511588 | 0.74 | L3MBTL1 (0.39) | CYP1A2ALDH1A1KDM4EHPGDCYP2C19 | |
| SCHEMBL10423608 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0344983-B1 | PROCESS FOR PREPARING 2- AND 4-ALKOXYCARBONYL THIOLAN-3-ONES | JOHN WYETH & BROTHER LIMITED (GB) | 1993-09-15 | — | — | EP | claimed |
| EP-0344983-A1 | Process for preparing 2- and 4-alkoxycarbonyl thiolan-3-ones | JOHN WYETH & BROTHER LIMITED (GB) | 1989-12-06 | — | — | EP | claimed |
| EP-4339199-B1 | SYNTHESIS OF CANTHARIDIN | VERRICA PHARMACEUTICALS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-3901151-B1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2026-04-01 | — | — | EP | disclosed |
| US-20250296928-A1 | A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-09-25 | — | — | US | disclosed |
| WO-2025119351-A1 | GPR139 AGONIST | 深圳湾实验室 | 2025-06-12 | — | — | WO | disclosed |
| CN-120035585-A | Process for the preparation of substituted aminothiophenes | 安道麦阿甘有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-20250115604-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2025-04-10 | — | — | US | disclosed |
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS INC (US) | 2025-03-27 | — | — | US | disclosed |
| CN-116265451-B | Preparation method of 4-methoxycarbonyl-2-methylthiophene-3-sulfonamide | 江苏瑞邦农化股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-12221452-B2 | Synthesis of cantharidin | VERRICA PHARMACEUTICALS INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-4144235-A | ANTIPSYCHOTIC, NEUROLEPTIC | AMERICAN CYANAMID COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
| US-4087421-A | NEUROLEPTIC, ANTI-DEPRESSANT AND ANALGESTIC ACTIVITY | AMERICAN CYANAMID COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
| US-4025630-A | Anesthesia methods using benzopyrans and esters thereof as pre-anesthesia medication | ABBOTT LABORATORIES (US) | 1977-05-24 | — | — | US | disclosed |
| US-4007272-A | Substituted benzodiazepin-10-ones in treating pain and depression | AMERICAN CYANAMID COMPANY (US) | 1977-02-08 | — | — | US | disclosed |
| US-3972880-A | TRANQUILIZER | SHARPS ASSOCIATES (US) | 1976-08-03 | — | — | US | disclosed |
| US-3960871-A | ANTIDEPRESSANT, ANALGESICS, ANTICONVULSANT ANTI-ANXIETY ACTIVITY | SHARPS ASSOCIATES (US) | 1976-06-01 | — | — | US | disclosed |
| US-3953430-A | ANTIDEPRESSANTS, ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
| US-3951981-A | NEUROLEPTIC, ANALGESIC | AMERICAN CYANAMID COMPANY (US) | 1976-04-20 | — | — | US | disclosed |
| US-3940421-A | Intermediates for the preparation of thienobenzopyrans and thiopyranobenzopyrans | ARTHUR D. LITTLE, INC. (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115604-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ENGASE, BACE1, GAA | KMT2A 973/4885BRD4 4319/4885CYP1A2 1194/4885 |
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, KRAS | KMT2A 1630/4885BRD4 1308/4885CYP1A2 1217/4885 |
| US-12221452-B2 | Synthesis of cantharidin | TYR, CMA1, DPM1 | KMT2A 4610/4885BRD4 449/4885CYP1A2 239/4885 |
| US-20250296928-A1 | A SYNTHESIS SCHEME AND PROCEDURES FOR PREPARING A SIK3 INHIBITOR AND INTERMEDIATES THEREOF | SIK3, SIK1, SIK2 | KMT2A 2822/4885BRD4 1284/4885CYP1A2 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.